# Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma

> **NCT06919679** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Cologne** · enrollment: 35 (estimated)

## Conditions studied

- Hodgkin Lymphoma (Category)

## Interventions

- **DRUG:** BrECADD

## Key facts

- **NCT ID:** NCT06919679
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2028-01
- **Final completion:** 2030-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919679, "Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06919679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*